DCAL

Dishman Carbogen Amcis Share Price

 

 

Invest in Dishman Carbogen Amcis with 2X leverage

Invest with MTF

Performance

  • Low
  • ₹208
  • High
  • ₹217
  • 52 Week Low
  • ₹178
  • 52 Week High
  • ₹322
  • Open Price₹212
  • Previous Close₹211
  • Volume203,974
  • 50 DMA₹236.84
  • 100 DMA₹245.59
  • 200 DMA₹246.11

Investment Returns

  • Over 1 Month -17.45%
  • Over 3 Month -29.33%
  • Over 6 Month -15.96%
  • Over 1 Year -14.11%

Smart Investing Starts Here Start SIP with Dishman Carbogen Amcis for Steady Growth!

Invest Now

Dishman Carbogen Amcis Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.8
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 3,298
  • P/B Ratio
  • 0.5
  • Average True Range
  • 12.39
  • EPS
  • 8.41
  • Dividend Yield
  • 0
  • MACD Signal
  • -8.33
  • RSI
  • 39.01
  • MFI
  • 32.21

Dishman Carbogen Amcis Financials

Dishman Carbogen Amcis Technicals

EMA & SMA

Current Price
₹210.32
-0.84 (-0.4%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹224.64
  • 50 Day
  • ₹236.84
  • 100 Day
  • ₹245.59
  • 200 Day
  • ₹246.11

Resistance and Support

211.64 Pivot Speed
  • R3 223.88
  • R2 220.24
  • R1 215.28
  • S1 206.68
  • S2 203.04
  • S3 198.08

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Dishman Carbogen Amcis Ltd. is a leading global contract research and manufacturing organization (CRMO) based in India, specializing in pharmaceutical and biotechnology services. The company focuses on providing high-quality, innovative solutions in API production and custom synthesis.

Dishman Carbogen Amcis has an operating revenue of Rs. 2,796.84 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company has a reasonable debt to equity of 20%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 23 which is a POOR score indicating inconsistency in earnings, a RS Rating of 42 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Dishman Carbogen Amcis Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-03 Quarterly Results
2025-12-27 To consider Fund Raising
2025-11-04 Quarterly Results
2025-08-12 Quarterly Results & Fund raising
2025-05-21 Audited Results

Dishman Carbogen Amcis F&O

Dishman Carbogen Amcis Shareholding Pattern

59.32%
1.08%
0%
7.66%
0%
27.31%
4.63%

About Dishman Carbogen Amcis

  • NSE Symbol
  • DCAL
  • BSE Symbol
  • 540701
  • Managing Director
  • Mr. Arpit J Vyas
  • ISIN
  • INE385W01011

Similar Stocks to Dishman Carbogen Amcis

Dishman Carbogen Amcis FAQs

Dishman Carbogen Amcis share price is ₹210 As on 06 February, 2026 | 04:46

The Market Cap of Dishman Carbogen Amcis is ₹3297.5 Cr As on 06 February, 2026 | 04:46

The P/E ratio of Dishman Carbogen Amcis is 27.8 As on 06 February, 2026 | 04:46

The PB ratio of Dishman Carbogen Amcis is 0.5 As on 06 February, 2026 | 04:46

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23